$TEVA Market Cap:
Research Board Inbox Deep Research Not Interested Shortlisted

$TEVA SEC Filings

Filing Filed On
TEVA ANNOUNCES APPROVAL OF GENERIC KYTRIL? INJECTION AND TABLETS 03 Jan 2008
TEVA ANNOUNCES APPROVAL OF GENERIC DUONEB? 03 Jan 2008
POST EFFECTIVE AMEND NO. 2 28 Dec 2007
TEVA ANNOUNCES LAUNCH OF GENERIC PROTONIX? TABLETS, 20 MG AND 40 MG,COMPANY INCR 26 Dec 2007
TEVA ANNOUNCES APPROVAL OF GENERIC TRILEPTAL? TABLETS 17 Dec 2007
TEVA TO PRESENT AT THE 2ND ANNUAL NASDAQ TASE ISRAELI INVESTOR CONFERENCE 03 Dec 2007
EARLY TREATMENT WITH COPAXONE? DEMONSTRATED ROBUST PROTECTION AGAINST PROGRESSIO 03 Dec 2007
TEVA ANNOUNCES TENTATIVE APPROVAL OF GENERIC REQUIP? TABLETS 03 Dec 2007
INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD 07 Nov 2007
FIRST PATIENT UNDERGOES EXPANDED CORD BLOOD TRANSPLANT IN THE EXCELL REGISTRATIO 07 Nov 2007
FORM 6-K 02 Nov 2007
TEVA ANNOUNCES PLANNED RETIREMENT OF CFO DAN SUESSKIND IN MID-2008 30 Oct 2007
TEVA REPORTS THIRD QUARTER 2007 RESULTS 30 Oct 2007
TEVA REPORTS THIRD QUARTER 2007 RESULTS 30 Oct 2007
COPAXONE? SIGNIFICANTLY DECREASES DISEASE ACTIVITY IN PATIENTS WHO SWITCHED FROM 23 Oct 2007
ADENOSCAN? PATENT LAWSUITS SETTLED 22 Oct 2007
TEVA TO REPORT THIRD QUARTER 2007 FINANCIAL RESULTS ON OCTOBER 30, 2007 18 Oct 2007
TEVA CALLS 0.375% REMAINING CONVERTIBLE DEBENTURES DUE 2022 FOR REDEMPTION 17 Oct 2007
LONG-TERM STUDY SHOWS COPAXONE? SIGNIFICANTLY SLOWS PROGRESSION OF DISABILITY AN 15 Oct 2007
TEVA ANNOUNCES APPROVAL OF GENERIC ACTONEL? 09 Oct 2007